Enhancing Existing Approaches to Peripheral T-Cell Lymphoma-Reference-Cited by-同舟云学术

Enhancing Existing Approaches to Peripheral T-Cell Lymphoma

Published:2010-04 Issue: Volume:47 Page:S8-S10
ISSN:0037-1963
Container-title:Seminars in Hematology
language:en
Short-container-title:Seminars in Hematology

Author:

Foss Francine M.

Publisher

Elsevier BV

Subject

Hematology

Reference18 articles.

1. Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracycline-based regimens: a comprehensive meta-analysis [abstr 3452];Abouyabis;Blood,2007

2. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes;Vose;J Clin Oncol,2008

3. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma;Tilly;Blood,2003

4. ESHAP chemotherapy regimen and 13-cis-retinoic acid in elderly patients with untreated poor-prognosis peripheral T cell lymphoma: a GELA phase II trial of feasibility and efficacy [abstr 322];Bouabdallah;Ann Oncol,2005

5. Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience;Arkenau;Haematologica,2007

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prospective International Multicenter Phase II Trial of Intravenous Pegylated Liposomal Doxorubicin Monochemotherapy in Patients With Stage IIB, IVA, or IVB Advanced Mycosis Fungoides: Final Results From EORTC 21012;Journal of Clinical Oncology;2012-11-20

2. Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01;Journal of Clinical Oncology;2012-09-01

3. Lymphome T périphérique : nouvelles substances adaptées à l’histologie ?;Oncologie;2011-09

4. Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas;European Journal of Haematology;2011-07-31

5. Guidelines for the management of mature T‐cell and NK‐cell neoplasms (excluding cutaneous T‐cell lymphoma);British Journal of Haematology;2011-04-11